Clinical Trials Logo

Filter by:
NCT ID: NCT03885752 Enrolling by invitation - Clinical trials for Postoperative Sore Throat

The Effects of Preoperatively Chewing Gum on Sore Throat After General Anaesthesia With a Laryngeal Mask

Start date: March 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Postoperative sore throat (POST) is an important problem after general anaesthesia. We assessed whether chewing gum preoperatively can reduce the incidence of POST after general anaesthesia administered via a streamlined liner of the pharyngeal airway (SLIPA).

NCT ID: NCT03851991 Enrolling by invitation - COPD Patients Clinical Trials

The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.

Start date: August 30, 2019
Phase: Phase 4
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world. Acute exacerbations of COPD (AECOPD) are the most important events in the course of the disease because they negatively impact health status, life quality, disease progression, patients survival and economic and social burden. Reducing frequency of AECOPD is the key goal of management for COPD. Since respiratory viral infections are the mainly trigger of AECOPD, anti-viral therapy would be the affective method to prevent the exacerbation or reduce the attack severity. However, there are no positive study results of treating or preventing AECOPD used by current anti-viral drugs approved by FDA so far. Arbidol is a non-nucleoside antiviral drug. It inhibits viral DNA and RNA synthesis by inhibiting fusion of viral lipid vesicle membrane with host cell membranes. Arbidol has broad-spectrum antiviral activity. In addition to inhibition of influenza virus, it against a variety of viruses including respiratory syncytial disease (RSV), parainfluenza virus, human rhinovirus, coxsackie virus (CV), adenovirus (ADV) and so on. In recent years, some fundamental and clinical researches have shown that arbidol has a significant role in prevention and treatment of influenza virus and other acute respiratory viral infections. Therefore, the investigators speculate that Arbidol will effectively control COPD combined with upper respiratory virus infection, thereby reducing acute exacerbations of COPD. This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 52-week study. The purpose of this study is to evaluate the efficacy and safety of arbidol in improving the frequency and extent of moderate or severe acute exacerbations in patients with COPD. Eligible subjects will be randomly assigned to treatment group or placebo group at a 2:1 ratio. Subjects of treatment group receive an on-demand arbidol 200 mg three times per day while placebo group receives matched placebo. When the subject has a new respiratory infection, original respiratory symptoms worsen, or fever (the lower body temperature is greater than 37.3℃), oral medication is given immediately. The subjects are required to receive the first dose of drug within 8 hours after the symptoms of upper respiratory tract infection.

NCT ID: NCT03845829 Enrolling by invitation - Clinical trials for Type B Aortic Dissection

LSA Reconstruction With Laser Fenestration During the TEVAR

LLTEVAR
Start date: July 1, 2018
Phase: N/A
Study type: Interventional

This study aims to evaluate the feasibility, effectiveness, and safety of in-situ laser-assisted fenestration on the left subclavian artery during the procedure of thoracic artery endovascular repair

NCT ID: NCT03841240 Enrolling by invitation - Clinical trials for Catheter-Related Infections

The Central Venous Catheter Related Complications in Critically Ill Patients

Start date: February 19, 2019
Phase:
Study type: Observational

In this prospective clinical study, the researchers investigate the incidence of catheter-related thrombosis and catheter-related infection during indwelling central venous catheterization in critically ill patients, and analyzed the risk factors for catheter-related complications and the relationship between catheter-related thrombi and catheter-related infections. The sample size is about 500.

NCT ID: NCT03837782 Enrolling by invitation - Laparoscopy Clinical Trials

Outcome of Resection for Colorectal Cancer

LRLCC
Start date: February 15, 2019
Phase: N/A
Study type: Interventional

There are limited data from retrospective studies regarding whether short-term and long-term outcomes after laparoscopic or robot-assisted radical colectomy (minimally invasive surgery) are equivalent to those after open abdominal radical colectomy (open surgery) among patients with early and medium-stage colorectal cancer. This trial is a multicenter,prospective, randomized trial evaluating short-term and survival outcomes concerning minimally invasive surgery and open surgery for colorectal cancer.

NCT ID: NCT03805165 Enrolling by invitation - Jaundice, Neonatal Clinical Trials

Hour-specific Transcutaneous Bilirubin in Healthy Term and Near-term Newborns of China

Start date: February 1, 2019
Phase:
Study type: Observational

Make a neonatal jaundiced nomogram on Chinese jaundice data by joinning the major neonate centers all around China.

NCT ID: NCT03802838 Enrolling by invitation - Schizophrenia Clinical Trials

Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia

Start date: October 1, 2017
Phase: Phase 4
Study type: Interventional

To explore the effects of combined traditional Chinese and Western medicine( Chinese acupuncture combined with Amisulpride Tablets) on negative symptoms, cognitive function and social function in patients with schizophrenia, and the side effects and safety of Chinese acupuncture combined with Amisulpride Tablets.

NCT ID: NCT03801200 Enrolling by invitation - NSCLC Clinical Trials

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Start date: September 10, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).

NCT ID: NCT03800160 Enrolling by invitation - Metabolic Surgery Clinical Trials

Greater China Metabolic and Bariatric Surgery Database

Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

Metabolic surgery, as a recognition treatment option for patients with clinical morbid obesity, is gaining increasing appreciation. In addition to substantial weight loss, emerging studies have highlighted that metabolic surgery can substantially ameliorate obesity-related metabolic diseases, including but not limited to type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, obstructive sleep apnea-hypopnea syndrome (OSAHS) and polycystic ovary syndrome (PCOS)in severely obese patients. However, further investigations with larger sample size and longer observation time still needed to clarity the efficacy and safety of metabolic surgery in Chinese patients with obesity and encouraging future research in this field.

NCT ID: NCT03767777 Enrolling by invitation - Clinical trials for Thoracic Aortic Dissection

Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY(PATENCY)

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

A prospective, multi-centre, objective performance criteria clinical trial to evaluate the safety and efficacy of Artery Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for the thoracic aortic dissection involving the aortic arch.